P. Ott

P. Ascierto, P. Ott, M. Hellmann, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies

D. Planchard, J. Schellens, W. Miller, 2019, Clinical Trials.

Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy

Nir Hacohen, Donna Neuberg, Derin B. Keskin, 2020, Scientific Reports.

1 A cloning and expression system to probe T cell receptor specificity and assess functional avidity to neoantigens Running Head : Defining T cell receptor specificity to neoantigen

K. Livak, N. Hacohen, Louise Williams, 2018 .

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

A. Ng, F. Hodi, B. Alexander, 2015, Oncoimmunology.

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.

D. Planchard, J. Schellens, W. Miller, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies

R. Sullivan, J. Sosman, Douglas B. Johnson, 2016, Cancer.

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

A. Giobbie-Hurder, F. Hodi, P. Ott, 2015, Cancer Immunology Research.

Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

G. Linette, J. Wolchok, F. Hodi, 2016 .

T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer

F. Hodi, P. Ott, 2015 .

The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.

F. Hodi, P. Ott, 2012, Chinese clinical oncology.

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

Y. Bang, P. Ott, S. Piha-Paul, 2015 .

Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy.

P. Ott, 2015, Annals of translational medicine.

Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?

P. Ott, J. Luke, 2013, Expert opinion on pharmacotherapy.

Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases

Ivan Buzurovic, P. Devlin, N. Ibrahim, 2022, JAAD case reports.

Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel.

H. Yee, P. Ott, A. Pavlick, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma

A. Giobbie-Hurder, R. Sullivan, K. Flaherty, 2018, Melanoma research.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Merrick I Ross, Susan M Swetter, Brian Gastman, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).

D. Jäger, P. Ascierto, P. Ott, 2016 .

Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.

P. Ott, Dong-Wan Kim, R. Moss, 2015 .

Intralesional Cancer Immunotherapies.

P. Ott, 2019, Hematology/oncology clinics of North America.

Phase II Trial of Dacarbazine and Thalidomide for the Treatment of Metastatic Melanoma

P. Ott, A. Pavlick, F. Muggia, 2009, Chemotherapy.

Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients

P. Ott, S. Pascolo, E. Romano, 2021, Journal for ImmunoTherapy of Cancer.

Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications.

F. Loop, E. Topol, S. Ellis, 1998, Journal of the American College of Cardiology.

A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013

P. Ott, Jennifer Y. Lin, C. Schmults, 2018, Journal of the American Academy of Dermatology.

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

P. Ott, I. Chau, D. Le, 2019, Gastric Cancer.

Personal Neoantigen Vaccines for the Treatment of Cancer

P. Ott, K. Shetty, 2021 .

Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study.

F. Hodi, P. Ott, H. Kaufman, 2014 .

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.

D. Matei, Ping Yang, P. Ott, 2019, Gynecologic oncology.

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

P. Sharma, F. D. De Braud, Han Chang, 2021, Clinical Cancer Research.

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.

P. Ascierto, A. Italiano, A. Santoro, 2022, The lancet. Gastroenterology & hepatology.

Genomic biomarkers in relation to PD-1 checkpoint blockade response.

J. Lunceford, Chunsheng Zhang, T. Mcclanahan, 2018 .

674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032

D. Jäger, P. Ascierto, P. Sharma, 2017 .

Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.

P. Ascierto, P. Sharma, P. Ott, 2017 .

Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study.

P. Ascierto, P. Sharma, P. Ott, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer.

M. Goldstein, R. Gaynor, P. Ott, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

R. Plummer, E. D. de Vries, P. Ott, 2021, Journal for ImmunoTherapy of Cancer.

Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.

D. Jäger, P. Sharma, P. Ott, 2018 .

Neoantigen-directed therapeutics in the clinic: where are we?

S. H. van der Burg, P. Ott, K. Thielemans, 2023, Trends in cancer.

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy

P. Ott, J. Henderson, D. Rao, 2023, Nature Communications.

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial

D. Jäger, P. Ascierto, P. Sharma, 2017 .

Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broadde novoanti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

M. Goldstein, R. Govindan, R. Gaynor, 2018, Clinical Trials.

A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition

A. Giobbie-Hurder, P. Ott, E. Buchbinder, 2023, Investigational new drugs.

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

D. Jäger, H. Wakelee, S. Ou, 2016 .

Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.

F. Hodi, P. Ott, S. Rodig, 2021 .

A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

H. Kohrt, J. Wolchok, F. Hodi, 2013 .

Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.

P. Ott, Y. Janjigian, Yoon-Koo Kang, 2018 .

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

P. Ascierto, P. Ott, M. Pietanza, 2015 .

A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.

Andrew J. Park, J. Wolchok, F. Hodi, 2015 .

427OPembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

H. Rugo, J. Schellens, K. Tamura, 2017 .

Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma

S. Adams, L. Chiriboga, P. Ott, 2013, Journal of Immunotherapy for Cancer.

Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy

Rebecca L. Holden, N. Hacohen, D. Neuberg, 2020, Scientific Reports.

A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.

Douglas B. Johnson, P. Ott, L. Hart, 2017 .

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

P. Ott, J. Luke, 2014 .

PD-1 inhibitors in endometrial cancer

P. Ott, R. Barroso-Sousa, 2017, Oncotarget.

Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.

A. Italiano, P. Ott, S. Piha-Paul, 2022, Gynecologic oncology.

Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.

S. Adams, L. Chiriboga, P. Ott, 2012 .

Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.

P. Ott, I. Chau, D. Le, 2019, Clinical colorectal cancer.

Precision cancer medicine: Concepts, current practice, and future developments

S. Fröhling, A. von Deimling, B. Geoerger, 2023, Journal of internal medicine.

A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

M. Suarez‐Almazor, D. Hafler, H. Tawbi, 2020 .

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma

A. Giobbie-Hurder, P. Ott, E. Buchbinder, 2023, Investigational New Drugs.

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy

P. Ott, A. Spektor, M. Awad, 2019, Front. Oncol..

General Principles of Immune-Related Toxicities

P. Ott, O. Rahma, 2019, SITC’s Guide to Managing Immunotherapy Toxicity.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab.

J. Lunceford, T. Mcclanahan, M. Ayers, 2017 .

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

P. Ott, J. Luke, 2014, Drug, healthcare and patient safety.

Novel therapeutics for melanoma

P. Ott, A. Pavlick, N. Seetharamu, 2009, Expert review of anticancer therapy.

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

P. Ascierto, F. Hodi, M. Sznol, 2015, Journal of Immunotherapy for Cancer.

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Alyssa R. Richman, Monika S. Kowalczyk, Shuqiang Li, 2018, Nature.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Monika S. Kowalczyk, A. Regev, P. Sorger, 2018, Cell.

Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

A. Giobbie-Hurder, F. Hodi, P. Ott, 2014, Clinical Cancer Research.

Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).

Douglas B. Johnson, P. Ott, G. Long, 2020 .

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

S. W. Han, D. Polsky, P. Ott, 2017, Oncology.

HLA-Binding Properties of Tumor Neoepitopes in Humans

N. Hacohen, Catherine J. Wu, V. Brusic, 2014, Cancer Immunology Research.

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

P. Ott, J. Luke, 2015, Oncotarget.

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

F. Hodi, P. Ott, C. Robert, 2013, Clinical Cancer Research.

Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

S. Adams, L. Chiriboga, P. Ott, 2015, Cancer Immunology Research.

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.

P. Ott, K. Papadopoulos, J. Infante, 2018, Cancer cell.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

S. Swetter, M. Ross, J. Torres-Roca, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients

F. Hodi, N. Ibrahim, P. Ott, 2017, Cancer immunology research.

Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.

M. Morgan, H. Rugo, Y. Bang, 2016 .

Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)

G. Linette, C. Horak, J. Wolchok, 2016 .

A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

M. Suarez‐Almazor, D. Hafler, H. Tawbi, 2022, Journal of Clinical Oncology.

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS

A. Giobbie-Hurder, F. Hodi, P. Ott, 2020, Gastroenterology.